UNSPSC 51263015: Trimazosin hydrochloride anhydrous

This classification denotes an alpha-adrenergic blocking agent with the molecular formula C20H29N5O6.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OT29P74170, chemically known as 1-piperazinecarboxylic acid, 4-(4-amino-6,7,8-trimethoxy-2-quinazolinyl)-, 2-hydroxy-2-methylpropyl ester, hydrochloride (1:1), but more generally known as trimazosin hydrochloride anhydrous, which bears US NIH Compound Identifier 64748.

European Medicines Agency schedules trimazosin hydrochloride anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11298MIG. Most nations, for tariff purposes, schedule trimazosin hydrochloride anhydrous under HS 29335995. SMILES: CC(C)(COC(=O)N1CCN(CC1)C2NC3C(CC(C(C3OC)OC)OC)C(N2)N)O.CL.

UNSPSC 51263015 Trimazosin hydrochloride anhydrous is a Commodity code representing pharmaceutical active pharmaceutical ingredients and finished-form drugs. Recent state and local procurement activity under this code shows minimal relevant alignment; the two most recent opportunities posted under it involve naloxone procurement and direct-to-manufacturer prescription programs rather than trimazosin hydrochloride specifically. State and local health agencies and pharmacy benefit programs use this code family to classify pharmaceutical acquisitions, but the recent solicitations demonstrate a mismatch between the code's nominal scope and the actual work being bought. Issuing bodies at the state and county level—including county health departments and state health and human services commissions—post pharmaceutical procurements under broad drug codes, though the specific active pharmaceutical ingredients vary widely by need.

Geographic activity appears concentrated in Florida and Texas based on the two most recent opportunities. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023—a historical mismatch in posted versus due dates that suggests data quality issues in the source record. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, posted as an exploratory market-intelligence exercise rather than a binding solicitation. The code shows little recent relevant activity specific to trimazosin hydrochloride procurement; business development professionals should verify whether opportunities tagged under this code actually require this ingredient or whether broader pharmaceutical or generic-drug codes better capture active state and local demand.